Announcements Trials
Browse Landscape

Phase

Phase 2 14Phase 1 8Phase 1/2 5Phase 3 4Phase EARLY_PHASE1 2Phase 4 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 60Neoplasms 24Prostatic Neoplasms 21Multiple Myeloma 17Carcinoma, Non-Small-Cell Lung 15Carcinoma, Hepatocellular 15Stomach Neoplasms 11Papillomavirus Infections 11Lung Neoplasms 11Colorectal Neoplasms 10Melanoma 9Pain, Postoperative 7Neoplasm Metastasis 7Leukemia, Myeloid, Acute 7Waldenstrom Macroglobulinemia 6Lymphoma, Non-Hodgkin 6Leiomyoma 6Hematologic Neoplasms 6Brain Neoplasms 6Smoking Cessation 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Polycystic Ovary Syndrome 5Pain 5Lymphoma 5Glioma 5Carcinoma, Renal Cell 5Venous Thromboembolism 4Uterine Cervical Neoplasms 4Urinary Bladder Neoplasms 4Tobacco Use Disorder 4

Interventions

olaparib 1enzalutamide 1Prednisone 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Metastatic Castration-resistant Prostate Cancer × 1 year × Clear all
NCT05457257 2026-04-21

Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations

AstraZeneca

Phase 4 Active not recruiting
43 enrolled 16 charts
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡